Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5700
- TODAY'S CHANGE (%)-0.0126 (-2.1627%)
- Bid / Lots0.5800/ 13
- Ask / Lots0.5899/ 20
- Open / Previous Close0.5885 / 0.5826
- Day Range
- 52 Week Range
- Volume302,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 406 | 0.5885 |
| 09:38 ET | 100 | 0.5711 |
| 09:39 ET | 100 | 0.5711 |
| 09:41 ET | 380 | 0.572 |
| 09:43 ET | 100 | 0.5725 |
| 09:45 ET | 100 | 0.5725 |
| 09:48 ET | 100 | 0.5826 |
| 09:50 ET | 1100 | 0.57755 |
| 09:52 ET | 100 | 0.5725 |
| 09:54 ET | 1588 | 0.5826 |
| 09:56 ET | 38065 | 0.57565 |
| 09:59 ET | 100 | 0.5711 |
| 10:01 ET | 100 | 0.5713 |
| 10:06 ET | 100 | 0.5713 |
| 10:08 ET | 300 | 0.574 |
| 10:10 ET | 100 | 0.5713 |
| 10:14 ET | 300 | 0.5765 |
| 10:17 ET | 100 | 0.5735 |
| 10:21 ET | 20000 | 0.579332 |
| 10:28 ET | 100 | 0.5726 |
| 10:32 ET | 100 | 0.5729 |
| 10:37 ET | 100 | 0.5729 |
| 10:39 ET | 10000 | 0.579 |
| 10:42 ET | 100 | 0.5729 |
| 10:44 ET | 100 | 0.5729 |
| 10:46 ET | 100 | 0.5729 |
| 10:48 ET | 100 | 0.57595 |
| 10:50 ET | 100 | 0.5729 |
| 10:53 ET | 200 | 0.5729 |
| 10:57 ET | 300 | 0.57435 |
| 11:02 ET | 100 | 0.57435 |
| 11:04 ET | 100 | 0.5743 |
| 11:06 ET | 1450 | 0.57325 |
| 11:08 ET | 250 | 0.574 |
| 11:09 ET | 1300 | 0.5725 |
| 11:13 ET | 100 | 0.5725 |
| 11:15 ET | 2500 | 0.571 |
| 11:18 ET | 300 | 0.57105 |
| 11:22 ET | 200 | 0.57105 |
| 11:26 ET | 100 | 0.57105 |
| 11:27 ET | 100 | 0.57105 |
| 11:31 ET | 1400 | 0.5711 |
| 11:36 ET | 100 | 0.57215 |
| 11:40 ET | 100 | 0.57215 |
| 11:47 ET | 100 | 0.57215 |
| 11:49 ET | 300 | 0.5732 |
| 11:54 ET | 100 | 0.57215 |
| 11:56 ET | 200 | 0.5733 |
| 12:03 ET | 100 | 0.5721 |
| 12:07 ET | 2558 | 0.57165 |
| 12:09 ET | 200 | 0.57165 |
| 12:14 ET | 100 | 0.57165 |
| 12:18 ET | 200 | 0.5716 |
| 12:20 ET | 100 | 0.5716 |
| 12:23 ET | 324 | 0.57 |
| 12:30 ET | 100 | 0.57 |
| 12:32 ET | 100 | 0.5716 |
| 12:34 ET | 100 | 0.57 |
| 12:38 ET | 1204 | 0.5701 |
| 12:39 ET | 100 | 0.5701 |
| 12:43 ET | 100 | 0.5701 |
| 12:45 ET | 2276 | 0.5731 |
| 12:48 ET | 1422 | 0.5779 |
| 12:54 ET | 100 | 0.57415 |
| 01:12 ET | 100 | 0.5703 |
| 01:14 ET | 100 | 0.5703 |
| 01:15 ET | 100 | 0.5703 |
| 01:17 ET | 100 | 0.5779 |
| 01:19 ET | 100 | 0.5703 |
| 01:21 ET | 272 | 0.574 |
| 01:26 ET | 100 | 0.574 |
| 01:28 ET | 1028 | 0.57405 |
| 01:32 ET | 100 | 0.5703 |
| 01:33 ET | 100 | 0.574 |
| 01:37 ET | 900 | 0.574 |
| 01:39 ET | 200 | 0.574 |
| 01:42 ET | 100 | 0.5703 |
| 01:48 ET | 100 | 0.5703 |
| 01:50 ET | 173 | 0.5775 |
| 01:51 ET | 100 | 0.57395 |
| 01:53 ET | 100 | 0.5703 |
| 01:57 ET | 200 | 0.5703 |
| 02:02 ET | 200 | 0.5728 |
| 02:04 ET | 100 | 0.5703 |
| 02:08 ET | 400 | 0.5703 |
| 02:11 ET | 1607 | 0.5703 |
| 02:13 ET | 1076 | 0.5717 |
| 02:18 ET | 100 | 0.5702 |
| 02:22 ET | 100 | 0.5702 |
| 02:26 ET | 100 | 0.5702 |
| 02:29 ET | 100 | 0.5702 |
| 02:36 ET | 500 | 0.5773 |
| 02:38 ET | 7100 | 0.57375 |
| 02:40 ET | 4024 | 0.5727 |
| 02:44 ET | 200 | 0.5702 |
| 02:49 ET | 100 | 0.5702 |
| 02:54 ET | 100 | 0.5702 |
| 02:58 ET | 100 | 0.5702 |
| 03:02 ET | 100 | 0.5702 |
| 03:05 ET | 272 | 0.5702 |
| 03:14 ET | 200 | 0.5737 |
| 03:16 ET | 100 | 0.5702 |
| 03:20 ET | 200 | 0.5736 |
| 03:23 ET | 100 | 0.5702 |
| 03:25 ET | 200 | 0.5703 |
| 03:30 ET | 100 | 0.5703 |
| 03:32 ET | 100 | 0.5703 |
| 03:34 ET | 610 | 0.5702 |
| 03:36 ET | 100 | 0.57355 |
| 03:38 ET | 100 | 0.5702 |
| 03:39 ET | 873 | 0.571 |
| 03:41 ET | 463 | 0.5702 |
| 03:43 ET | 990 | 0.5702 |
| 03:45 ET | 100 | 0.5702 |
| 03:48 ET | 300 | 0.5702 |
| 03:50 ET | 100 | 0.5702 |
| 03:52 ET | 3519 | 0.5701 |
| 03:54 ET | 400 | 0.5701 |
| 03:56 ET | 300 | 0.5701 |
| 03:57 ET | 600 | 0.5702 |
| 03:59 ET | 109502 | 0.57 |
Sep 4, 2024
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference, from 4:01PM ET on Wednesday Sep 04, 2024 by Dow Jones
4:01PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 42.5M | -0.4x | --- |
LAVA Therapeutics NV | 44.2M | -1.8x | --- |
DURECT Corp | 42.5M | -2.5x | --- |
Atara Biotherapeutics Inc | 44.9M | -0.2x | --- |
Kronos Bio Inc | 57.1M | -0.6x | --- |
Bolt Biotherapeutics Inc | 24.1M | -0.4x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Chief Executive Officer, Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.5M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 73.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.35 |
Book Value | $2.58 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,531.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
